
Zoetis UK has launched Lenivia (izenivetmab injection) in Great Britain, a long-acting monoclonal antibody therapy for the alleviation of pain associated with osteoarthritis (OA) in dogs. The company announced the launch on 24 September 2026.
Lenivia is designed to provide up to three months of OA pain alleviation from a single subcutaneous injection. The treatment targets nerve growth factor (NGF), a recognised mediator of pain and inflammation, and binds to a different site on NGF from already commercialised anti-NGF monoclonal antibodies, according to Zoetis.
Zoetis said the therapy is supported by a nine-month European field study in which Lenivia demonstrated a sustained reduction in pain. The company reported that effects were observed from as early as Day 7 following the first injection. The product is administered once every three months.
The launch addresses the management of a chronic condition that Zoetis says may affect nearly 40 percent of dogs, regardless of size or age. The company also linked the growing number of senior pets to increased demand for long-term management of age-associated conditions such as osteoarthritis.
Tim Burgess, General Manager, Zoetis UK, said, “Lenivia gives veterinary professionals in Great Britain a new, long-acting option that can help alleviate osteoarthritis-associated pain with a single injection lasting up to three months. That longer dosing interval can also make it easier for owners to remain compliant, which matters in a condition that needs ongoing management.”
Zoetis said Lenivia builds on its existing OA pain portfolio for dogs and forms part of its broader animal-health pipeline.

































